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NeuroblastomaMolecular targeting of drug delivery nanocarriers is expected to improve their therapeutic index while de-
creasing their toxicity. Here we report the identiﬁcation and characterization of novel peptide ligands speciﬁc
for cells present in high-risk neuroblastoma (NB), a childhood tumor mostly refractory to current therapies.
To isolate such targeting moieties, we performed combined in vitro/ex-vivo phage display screenings on NB
cell lines and on tumors derived from orthotopic mouse models of human NB.
By designing proper subtractive protocols, we identiﬁed phage clones speciﬁc either for the primary tumor,
its metastases, or for their respective stromal components. Globally, we isolated 121 phage-displayed
NB-binding peptides: 26 bound the primary tumor, 15 the metastatic mass, 57 and 23 their respective micro-
environments. Of these, ﬁve phage clones were further validated for their speciﬁc binding ex-vivo to biopsies
from stage IV NB patients and to NB tumors derived from mice. All ﬁve clones also targeted tumor cells and
vasculature in vivo when injected into NB-bearing mice. Coupling of the corresponding targeting peptides
with doxorubicin-loaded liposomes led to a signiﬁcant inhibition in tumor volume and enhanced survival
in preclinical NB models, thereby paving the way to their clinical development.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Neuroblastoma (NB) is the most common extracranial solid tumor
in children, accounting for about 8% of childhood cancers. Approxi-
mately 40% of NB tumors are classiﬁed as high-risk; their manage-
ment includes combinations of chemotherapy, autologous stem cell
transplantation, surgery, and radiation therapy. Despite this aggressiveLaboratory of Oncology, Istituto
42; fax: +39 0103779820.
.it (M. Ponzoni),
.V. Open access under CC BY-NC-ND litreatment, children with high-risk NB have very poor 5-year overall
survival rate, due to relapsed and/or treatment-resistant tumors [1,2].
A further increase in therapeutic dose intensity is not feasible, because
it will lead to prohibitive short-term and long-term toxicities. New ap-
proaches with targeted therapies may improve efﬁcacy and decrease
toxicity [3].
Extensive investigation of NB biology has recently resulted in the
identiﬁcation of a wide range of potential druggable targets, most of
which are commonly deregulated in different solid tumors, e.g.,
disialoganglioside GD2 [3], anaplastic lymphoma kinase (ALK) [4], au-
rora kinase A (AURKA) [5], epidermal growth factor receptor (EGFR)
[6], insulin growth factor 1 receptor (IGF1R) [7], mammalian target
of rapamycin (mTOR) [7], and vascular endothelial growth factor re-
ceptor 2 (VEGFR2) [8]. Several compounds have proved to be highly
active in preclinical models, and at least 15 genes are presently in
the clinical pipeline as targets for NB therapy [9]. However, smallcense.
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limitations, including toxic side effects, induction of resistance, and
low response rates. Together, reports from the literature and from
clinical trials provide evidence that, unfortunately, for more than
50% of patients with high-risk NB there are substantially no curative
options available.
The use of drug delivery systems allows site speciﬁc delivery of
higher payload of active agents associated with lower systemic toxic-
ities compared to the use of conventional (‘free’) drugs; the possibil-
ity of imparting selectivity to the carrier to the cancer foci through the
use of a targeting moiety (e.g., a peptide or an antibody) further en-
hances drug efﬁcacy and safety [10–13]. The peptide motifs, NGR
[14] and CPRECES [15], home to the vasculature of different tumor
types and we have recently exploited them to vehiculate chemother-
apeutic agents to tumor blood vessels in preclinical models of NB
[16–18]. However, NB-targeting peptides with greater selectivity,
which are expected to substantially improve current therapeutic reg-
imens, have not been identiﬁed thus far.
We report here the identiﬁcation of novel peptide ligands, select-
ed by combined in vitro/ex-vivo phage display screenings in preclini-
cal models of human NB. Five sequences with differential speciﬁcity
for either epithelial or stromal components of the tumors were vali-
dated in vitro and in vivo for their targeting speciﬁcity. The capability
of peptide-targeted drug delivery systems to counteract tumor pro-
gression was investigated in biologically relevant murine models of
human NB. We demonstrated that this approach allows a substantial
improvement in therapeutic efﬁcacy compared to both free drug and
untargeted systems.
2. Materials and methods
2.1. Cells lines and human samples
The neuroblastoma (NB) cell lines (GI-LI-N, HTLA-230 and IMR-32)
were grown in complete Dulbecco's Modiﬁed Eagle Medium (DMEM)
or RPMI-1640 medium, as previously described [16,19]. Human
umbilical vein endothelial cells (HUVECs) were maintained in endo-
thelial cell basal medium-2 (Cambrex Bio Science), as described [20].
Cells were tested for mycoplasma contamination and characterized
by cell proliferation, morphology evaluation, and multiplex short
tandem repeat proﬁling test. Human samples (07-B-822, 07-B-1173
and 07-B-1312A2) derived from stroma poor, stage IV, NB patients,
were provided, after informed consent, by Bio-bank, Istituto Giannina
Gaslini, Genoa, Italy.
2.2. Animal models
Animals were purchased from Harlan Laboratories (Harlan Italy, S.
Pietro al Natisone, Italy) and were housed under pathogen-free con-
ditions; experiments were reviewed and approved by the licensing
and ethical committee of IRCCS Azienda Ospedaliera Universitaria
San Martino — IST Istituto Nazionale per la Ricerca sul Cancro
(Genoa, Italy), and by the Italian Ministry of Health. For the orthotipic
model, 5-week-old athymic (nu/nu) female mice were injected with
1 × 106 GI-LI-N or HTLA-230 cells in the left adrenal gland, as de-
scribed [16]. No mice died as a result of the surgery. Animals were
monitored at least twice a week for evidence of tumor development
and quantiﬁcation of tumor size, and were sacriﬁced by cervical
dislocation after being anesthetized with xilezine (Xilor 2%, Bio98
Srl, Milan, Italy), when they showed signs of poor health, e.g. abdom-
inal dilation, dehydration, or paraplegia. For the pseudometastatic
model, 4-week-old female athymic (nu/nu)micewere injected intrave-
nously (i.v.) in the tail vein with 4 × 106 HTLA-230 cells, as previously
described [19]. Body weight and general physical status were recorded
daily, and mice were sacriﬁced by cervical dislocation after the admin-
istration of xilezine, when they showed signs of poor health.2.3. Phage display biopanning on preclinical models of human
neuroblastoma
Cultured GI-LI-N and HTLA-230 cells were detached with 0.25%
trypsin-ethylene diamino tetra-acetic acid (EDTA) solution (Invitrogen,
Milan, Italy). Fresh tissues from orthotopically implanted GI-LI-N and
HTLA-230 animal models were dissected with a scalpel in Iscove's
Modiﬁed Dulbecco's Minimum Essential Medium (IMDM supplemented
with 2% fetal calf serum, FCS) in bath ice. 1010 transducing units (T.U.) of
a X7 (X = any amino acid) phage library (Ph.D.™-7 Phage Display
Peptide Library Kit, New England Biolabs, Ipswich, MA) was added to
5 × 105 target cells in binding medium, and incubated for 4 h at 4 °C
(ﬁrst round). For successive rounds, phages were ﬁrst pre-adsorbed
on control cells/tissues for 1 h at 4 °C and were subsequently incu-
bated with target tissues for 2 h at 4 °C. After 5 washes in binding
medium, bound phages were recovered and ampliﬁed by infection
of K91Kan Escherichia coli bacteria in log-phase. Phage particles
were puriﬁed from bacterial culture supernatants by precipitation
in NaCl/poly(ethylene glycol-8000) and titrated as described [21,22];
phage DNA was extracted and sequenced following the instructions of
the Ph.D.™-7 kit (New England Biolabs).
2.4. Ex-vivo validation of phage clones targeting neuroblastoma tissues
Fifteen phage clones, chosen on the basis of the presence of re-
peated tripeptide motifs, were validated for their binding to NB tis-
sues both from patients with stage IV NB and mice orthotopically
implanted with GI-LI-N cells. Tumors, frozen in optimum cutting tem-
perature (OCT) medium (Miles Chemical Co., Elkhart, IN), were cut in
5 μm-sections, ﬁxed in 4% paraformaldehyde in PBS for 10 min at
room temperature, and histologically evaluated by staining with
Mallory Trichrome (Bio-Optica, Milan, Italy). For the phage overlay
binding assay, sections were washed twice in phosphate buffered sa-
line (PBS), saturated with Protein Block Serum-Free (DAKO, Milan,
Italy), and overlayed for 1 h at 4 °C with 108 T.U./μL of each phage
clone. After extensive washing, phages were revealed by staining
with a rabbit anti-fd bacteriophage antibody (1:100, Sigma, St.
Louis, MO) and DcEnVision + System HRP (DAKO, Milan Italy) as
substrate. Non-epithelial tumor components were identiﬁed by stain-
ing with rabbit polyclonal anti-Factor VIII (1:100, DAKO), rat mono-
clonal anti-CD31 (1:100, BD Biosciences, Franklin Lakes, NJ), Cy3-
conjugated anti-α-smooth muscle actin mouse monoclonal (SMA-Cy3,
1:200, Sigma), and rabbit polyclonal anti-collagen I (1:200, AbCam,
Cambridge, UK). For immunoﬂuorescence staining and confocal analy-
ses (TCS SP2 confocal microscope, Leica Microsystems, Mannheim,
Germany), AlexaFluor® secondary antibodies (Invitrogen) were used.
2.5. Synthesis and in vitro validation of the NB-targeting peptides
To reproduce the original molecular environment of their phage-
displayed counterpart, selected NB-targeting peptides were synthe-
sized with the addition of the YSHS and GGG sequences at their N- and
C-terminal, respectively. To favor the accessibility of liposome-bound
peptides and to allow their coupling to maleimido groups (see
below), an additional Cys residue was inserted at their C-terminal,
resulting in the following peptide sequences (the NB-binding motifs
are underlined): #1: YSHSYEGLISRGGGC; #5: YSHSHSYWLRSGGGC;
#8: YSHSWSWPRELGGGC; #10: YSHSALAAHKLGGGC; #14: YSHS
KSFFLSHGGGC. In some experiments, the scrambled (SCR) peptide
YSHSLAKALHAGGGC was used as a control. For the cellular association
assays, biotin-conjugated NB-targeting peptides (concentration range:
20–200 μg/mL) were incubated with 1 × 106 cells for 1 h at 4 °C. Sam-
ples were washed in PBS, followed by incubation for 30 min with
Cy3-labeled streptavidin (Cy™3-Streptavidin, GE Healthcare). After
extensive washing, Cy3-positive cells were counted by ﬂow cytometry,
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Systems).
2.6. Preparation of neuroblastoma-targeted liposomes
Stealth™ liposomes (SL) were synthesized from HSPC:CHOL:
DSPE-PEG2000, 2:1:0.1 molar ratio, and HSPC:CHOL:DSPE-PEG2000:
DSPE-PEG2000-MAL, 2:1:0.08:0.02 molar ratio, as previously de-
scribed [16]. The hydrated liposomes were sequentially extruded
(LiposoFast-basic extruder, Avestin, Inc., Leiden, Holland) through
polycarbonate ﬁlters of pore size ranging from 0.2 μm down to
0.1 μm to produce primarily unilamellar vesicles. SL size, polydisper-
sity, and zeta-potential were analyzed by dynamic light scattering
using the zeta sizer Nano-S particle sizer at a ﬁxed angle (90°)
(Malvern Instruments, Malvern, UK). Doxorubicin (DXR) was loaded
into SL via an ammonium sulfate gradient, as previously reported
[19]. Targeted SL were produced by mixing freshly-prepared
nanocarriers with an equimolar (with respect to DSPE-PEG2000-MAL)
amount of peptide for 16 h at 4 °C under argon, followed by incubation
in a 10-fold excess of 2-mercapethanol for 1 h to neutralize remaining
maleimido groups. Uncoupled peptides were removed by passing the
reaction mixture through a Sepharose CL-4B column in HEPES buffer,
pH 7.4. Coupling efﬁciency was determined by the quantiﬁcation
of SL-associated peptides with the CBQCA Protein Quantiﬁcation Kit
(Molecular Probes Europe, Leiden, The Netherlands), as described [18].
3H- and 14C-dual labeled targeted liposomes were synthesized as
previously described [23].
2.7. Cell apoptosis and viability assays
Detection of apoptotic/hypodiploid cells was performed as de-
scribed [24]. Brieﬂy, GI-LI-N (6 × 105/well), HTLA-230 (6 × 105/
well) and HUVECs (1.2 × 106/collagen-pre-coated well) were seeded
in 6-well plates in complete medium; after 24 h, 50 μM of DXR en-
capsulated in either untargeted or peptide-targeted SL was added to
the culture medium and cells were incubated for 1 h at 37 °C. Cells
were then washed twice in PBS and cultured in fresh medium for an
additional 47 h, before being incubated in 3.4 mM sodium citrate,
20 μg/mL propidium iodide (PI) (Sigma) and 100 μg/mL RNase A
(Qiagen Italy, Milan, Italy) for 30 min at 37 °C in the dark.
For proliferation and cell cycle evaluation, untargeted or
peptide-targeted SL-treated cells were pulse-labeled with 10 μmol/L
bromodeoxyuridine (BrdU; Sigma) for 30 min, as previously reported
[20]. BrdU uptake was detected by cell staining with FITC-conjugated
mouse monoclonal anti-BrdU antibody (Becton Dickinson) at a ﬁnal
concentration of 5 μg/mL for 30 min at room temperature. After ex-
tensive washing, cells were resuspended in PBS containing 5 μg/mL
PI and the distribution of BrdU (FITC) versus DNA content (PI) was
assessed by ﬂow cytometry. In all the experiments, SCR-SL[DXR]
were used to validate the peptides targeted, DXR-loaded liposomes-
driven cytotoxic effects.
2.8. In vivo homing of neuroblastoma-targeted phage clones and of
neuroblastoma-targeted liposomes
For the phage homing studies, mice bearing orthotopic implants of
GI-LI-N cells were inoculated i.v. into the tail vein with 1 × 109 T.U. of
each NB-targeting phage clone. Animals were perfused with complete
medium at 10 min and 24 h after inoculation before being eutha-
nized; tumors and healthy organs were collected and ﬁxed in Bouin
solution. Four micrometer tissue slices were stained with the anti-fd
bacteriophage and anti-SMA-Cy3 antibodies using standard protocols.
Fluorescence was examined with a Laser Scanning Spectral confocal
microscope (TCS SP2, Leica MicroSystems). Staining was quantiﬁed on
3–5 confocal images/experimental point by using the Image Processing
and Analysis software in Java (ImageJ). Furthermore, digital imageswere processed with Adobe Photoshop CS2 (Adobe Systems, San
Jose, CA) to adjust contrast and assemble the ﬁnal plates. For the
tumor accumulation studies, 35 days after orthotopic tumor cell im-
plantation (mean volume ~250 mm3), mice received a single injec-
tion of untargeted or peptide-targeted SL containing-encapsulated
DXR (5 mg/kg/mouse). Twenty-four hours after the injection, mice
were sacriﬁced, tumors were collected, and DXR accumulation was
visualized by ﬂuorescence microscopy of cryopreserved tissue
sections.
2.9. Pharmacokinetic and biodistribution experiments
For pharmacokinetic studies, mice were injected via the tail vein
with either a single dose or two doses (7 day interval) of
peptide-targeted, dual-labeled liposomes, as previously described
[18,23]. At selected time points (2–48 h) post-injection, mice (three
mice/group) were anesthetized and sacriﬁced by cervical dislocation.
A blood sample (100 μL) was collected by heart puncture and count-
ed for the [3H]- and [14C]-labels in a Packard beta-counter. Blood
correction factors were applied to all samples as reported [23].
Biodistribution was performed in mice orthotopically implanted
with NB GI-LI-N cells, as previously reported [23].
2.10. In vivo therapeutic studies and tumor imaging
Mice bearing the orthotopic model were treated starting from day
21 after NB cell implant; mice with the pseudo-metastatic model re-
ceived the ﬁrst treatment 4 h after NB cell injection. These therapeutic
schedules were designed to test the effects of our targeted formulations
against both established and pseudo-metastatic preclinical models of
human NB, as described [16,19]. Animals were treated i.v. once a week
for 3 weeks with untargeted (SL[DXR]) or peptide-targeted SL[DXR]
(5 mg/kg). Scrambled peptide-functionalized liposomes were used as
a control, and in every experiment a group of control mice received
HEPES-buffered saline. Survival times were used as the main criterion
for determining treatment efﬁcacy. In the orthotopic model, time-
dependent anti-tumor activity was also evaluated by bioluminescence
imaging (BLI) and X-ray analyses. For this purpose, the GI-LI-N cell
line was infected with a retrovirus expressing the ﬁreﬂy luciferase
gene, as previously reported [17]; luciferase activity of retrovirally-
transduced cells was visualized in vivo by BLI (IVIS Caliper Life
Sciences, Hopkinton, MA) after a 10 min incubation with 150 μg/mL of
D-luciferin (Caliper Life Sciences), as described [17]. X-ray analysis was
superimposed to the luminescence for a better visualization of the
tumors.
2.11. Statistics
Results are expressed as mean ± conﬁdence intervals (95% CI). All
the analyses were performed with Prism 5 software (GraphPad, La
Jolla, CA): either Student's t test or two-way analysis of variance
(ANOVA) followed by Bonferroni's post-test were used to evaluate dif-
ferences within treatments; survival curves were drawn as Kaplan–
Meier Cumulative Proportion Surviving graphs, and corresponding
p-values were calculated by the use of the log-rank (Chi square) test.
Asterisks indicate the following p-value ranges: §,* = p b 0.05, §§,
** = p b 0.01, §§§,*** = p b 0.001.
3. Results
3.1. Identiﬁcation of neuroblastoma-targeting peptide ligands by
combined in vitro/ex-vivo phage display screenings
We rationalized combinations of in vitro (neuroblastoma (NB) cell
lines: GI-LI-N and HTLA-230) and ex-vivo (tissues from healthy ani-
mals and from orthotopic NB models) phage display screenings to
236 M. Loi et al. / Journal of Controlled Release 170 (2013) 233–241
N
A
N
O
M
E
D
IC
IN
Eidentify peptide ligands speciﬁc for: (i) whole tumor masses [Experi-
ment #1: negative pre-selection on kidney and adrenal gland from
healthy mouse, target selection on GI-LI-N-derived primary tumor;
Experiment #2: pre-selection on GI-LI-N-derived primary tumor, se-
lection on corresponding pancreatic metastasis] or (ii) tumor micro-
environments [Experiment #3: pre-selection on HTLA-230 cells,
selection on HTLA-230-derived primary tumor; Experiments #4 and
5: pre-selection on GI-LI-N cells, selection on GI-LI-N-derived primary
tumor from a different mouse; Experiment #6: pre-selection on
GI-LI-N cells, selection on GI-LI-N-derived metastasis]. We obtained
enrichments of target phage binding over the controls in the follow-
ing selection rounds (values reported in parenthesis): Experiment
#1: Round II (3.57×); Experiment #2: Round II (1.85×); Experiment
#3: Round III (3.90×); Experiment #4: Round IV (3.47×); Experi-
ment #5: Round IV (1.79×); Experiment #6: Round IV (1.32×). We
globally puriﬁed 300 NB-binding phage clones, displaying 121 single
peptide sequences; of these, 26 were selected for binding to the pri-
mary tumor mass (Experiment #1), 15 to the metastatic mass (Exper-
iment #2), 57 (Experiments #3–5) and 23 (Experiment #6) to their
respective microenvironments (the corresponding experimental
ﬂowchart is reported in Fig. 1).
3.2. Ex vivo and in vivo validation of neuroblastoma-targeted
phage-displayed peptides
We performed a ﬁrst validation on a panel of phage clones select-
ed in the different experiments (n = 15) by ex-vivo overlay binding
assays on tumor biopsies from NB patients. Ten out of the 15 selected
phage clones showedweak or no binding (data not shown). However,
ﬁve phages displayed peptides capable of high speciﬁc binding, com-
pared to the background and to the control insertless phage (Fd-Tet),
proving to be speciﬁc ligands for human NB, namely, KSFFLSH (Phage
#14, Experiment #2), YEGLISR (Phage #1, Experiment #3), HSYWLSR
(Phage #5, Experiment #4), WSWPREL (Phage #8, Experiment #5),
ALAAHKL (Phage #10, Experiment #5) (Figs. 1 and 2A). We observed
that Phages #1, #5, #8, and #10 preferentially bind to non-epithelial
tumor components, while Phage #14 widely recognizes the whole NB
masses, as suggested by comparative histological analyses (Mallory
Trichrome staining) performed on sections from the same human
NB samples. We further validated the binding of these phage clones
on tissue sections from mice bearing orthotopic implants of GI-LI-N
cells. In this case, the stromal components of tumor masses wereFig. 1. Flowchart of the phage display experiments. Combinations of in vitro (cell lines)
and ex-vivo (tumor tissues) negative/target selection screenings were rationally
designed to isolate peptide sequences speciﬁc for the whole tumoral mass or for its
stromal components.further characterized by staining for different speciﬁc markers, i.e.,
von Willebrand factor (FVIII), CD31, α-smooth muscle actin (SMA),
and Collagen I (Fig. 2B). These assays revealed that mouse (stromal)
components are also well-targeted, as supported by a comparison be-
tween phage targeting of selected tumor components and staining for
the stromal markers, supporting the rationale for in vivo preclinical
applications.
To evaluate the capability of the selected phage clones to target
tumors in vivo, mice, bearing in the left adrenal gland orthotopic
implants of GI-LI-N cells, were injected i.v. with either NB-targeting or
control insertless (Fd-Tet) phage, before being perfused and sacriﬁced.
Phage accumulation was revealed by decoration of explanted tissues
with an anti-fd bacteriophage antibody, and perivascular cells were
evidenced by staining for SMA. As shown in Fig. 3A, Fd-Tet did not accu-
mulate in tumor tissues, even after 24 h of circulation; on the contrary,
all the targeting phages showed speciﬁc homing to NB tumors by
10 min after administration. Interestingly, Phages #1, #5 and #10 pro-
gressively accumulated into the NB tumors over time, while Phages #8
and #14 were detectable at lower level in tumors explanted after 24 h
(Fig. 3A). These data could support the assumption that, although all
the selected phage-displayed peptides recognize NB-speciﬁc markers,
they might have different targeting properties, e.g. target availability
or afﬁnity. Importantly, negligible phages accumulation was observed
in healthy tissues, such as ipsilateral and contralateral kidneys, liver
and spleen (Fig. 3B).
Our ﬁndings suggest that, due to their substantial presence at the
diseased sites at 24 h post-administration, Peptides #5 and #10 have
the potential to be the best performers for in vivo applications.
3.3. Production and characterization of neuroblastoma-targeted drug
delivery nanocarriers
As a ﬁrst step toward the engineering of peptide-based modular
nanotherapeutics, we synthesized biotin-conjugated peptidesFig. 2. Selected phage-displayed peptides target human neuroblastoma from patients
and from orthotopically implanted mouse model ex-vivo. A. The 5 NB-targeting
phage clones, and the negative control insertless phage (Fd-Tet) were evaluated for
their speciﬁcity by phage overlay binding assays on 5-μm frozen sections from patients
with stage IV NB (07-B-822, 07-B-1173 and 07-B-1312A2). Tissue-bound phage clones
were detected by staining with a speciﬁc anti-bacteriophage antibody, followed by in-
cubation with DcEnVision + System HRP. Tissues were counterstained with hematox-
ylin. Overall tissue histology was evaluated by Mallory Trichrome staining. Of the 15
phage clones investigated, the 5 validated as NB-targeting (i.e., #1, #5, #8, #10, #14),
and the Fd-Tet are shown. B. The 5 NB-targeting clones and the Fd-Tet were also vali-
dated by overlay binding assays on tumor derived from orthotopic implants of GI-LI-N
cells in athymic mice, with the procedure described above. To identify the different cell
types composing tumor mass, adjacent sections were stained with antibodies speciﬁc
for Factor VIII, CD31, SMA and Collagen I. Sections were counterstained by hematoxy-
lin. Overall tissue histology was evaluated by Mallory Trichrome staining.
Fig. 3. Neuroblastoma-speciﬁc phage clones target an orthotopically implanted mouse
model of human NB and spare targeting healthy tissues in in vivo experiments. The ca-
pability of the NB-targeting phage clones to home to tumors was evaluated after their
i.v. administration into mice bearing human GI-LI-N NB-derived orthotopic xenografts
(3 animals/group). Insertless Fd-Tet phage was injected as a negative control. After
10 min and 24 h, mice were perfused with complete medium and euthanized. Tumor
tissues were explanted, Bouin-ﬁxed, parafﬁn-embedded and co-stained with anti-fd
bacteriophage (green) and anti-SMA-Cy3 (red) antibodies (A). B. Experiments were
performed as described in A. Healthy ipsilateral and controlateral kidneys, liver and
spleen were explanted, Bouin-ﬁxed, parafﬁn-embedded and stained with anti-fd bac-
teriophage antibody. Stainings were quantiﬁed on 5 confocal images/experimental
point by ImageJ software and presented by histograms. Symbols used to report the sta-
tistical analysis: * = peptide-displaying versus insertless phage; § = 24 h versus
10 min phage circulation. *, p b 0.05; **, §§, p b 0.01; ***, §§§, p b 0.001.
Fig. 4. Speciﬁc cell binding and cytotoxicity of neuroblastoma-targeted conjugates. A.
Biotin-conjugated peptides were investigated for their capability to bind to NB cell
lines (GI-LI-N, HTLA-230 and IMR-32) and to primary endothelial cells (HUVECs).
Binding was evaluated by incubation with Cy3-Streptavidin, and was quantiﬁed by
ﬂow cytometry. A scrambled peptide (SCR) was used as a negative control, and binding
is expressed as mean relative ﬂuorescence intensity (MRFI) normalized over cell stain-
ing with Cy3-labeled streptavidin (Cy3) only. Experiments were repeated 5 times.
Columns depict the fold increase ﬂuorescence intensity of each sample over control,
considering 1.00 the level of control; errors bars indicate 95% C.I. *, p b 0.05; **,
p b 0.01; ***, p b 0.001 versus SCR-biotin. B. The cytostatic effects of peptide-
functionalized liposomes were evaluated in HTLA-230 and HUVECs, by both PI staining
(B, upper panel, to quantify cells in sub-G0) and BrdU uptake (B, lower panel, to quan-
tify cells in S phase). Values are expressed as percent of the controls. *, p b 0.05; **,
p b 0.01; ***, p b 0.001 versus SL[DXR].
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The maintenance of their binding properties was tested by in vitro
association studies on human NB cell lines (GI-LI-N, HTLA-230
and IMR-32) and on human endothelium (HUVECs). Cells were in-
cubated with 20, 100, and 200 μg/mL of biotin-labeled peptides for
1 h at 4°°C, and their binding was evaluated by ﬂow cytometry
analysis. Compared to the scrambled (SCR) peptide, all the pep-
tides selectively recognized NB tumor cells and, at lower extent,
HUVECs (Fig. 4A). Notably, as observed with the in vivo phage hom-
ing (compare to Fig. 3), peptides corresponding to Phages #5 and
#10 showed the highest cellular association.
Having demonstrated the NB-targeting properties of the selected
peptides, we analyzed whether they could effectively target
nanocarriers encapsulating a chemotherapeutic drug, by ﬁrst produc-
ing untargeted and targeted doxorubicin (DXR)-loaded liposomes
(SL). Untargeted SL were not functionalized, or functionalized with
a scrambled (SCR) peptide and NB-targeted SL were functionalized
with Peptides #1, #5, #8, #10, and #14. From this point on, these for-
mulations will be reported as SL[DXR], SCR-SL[DXR], 1-SL[DXR], 5-SL
[DXR], 8-SL[DXR], 10-SL[DXR], and 14-SL[DXR], respectively. Lipo-
somes were typically 135 ± 10 nm in diameter, with a polydispersity
of 0.06 ± 0.01, and a z-potential value of−28 ± 2 mV in water and
of −2.4 ± 0.7 mV in PBS. The DXR entrapment efﬁciency was ~95%,
with an average coupling efﬁciency of 10 μg peptide/μmol phospho-
lipids (PL).
We ﬁrst tested the NB-targeted liposomes for their effects
against tumor and endothelial cells in vitro. Cells were treated for
1 h with 50 μM of DXR encapsulated in either untargeted (SL[DXR])
or peptide targeted SL before evaluating the percentage of apoptotic/
hypodiploid cells. In terms of cell cycle arrest, the percentage of NB
cells, i.e., HTLA-230 or GI-LI-N (not shown), in sub-G0 phase was signif-
icantly increased, compared with SL[DXR] and SCR-SL[DXR], by incuba-
tionwith all the targeted formulations (5-SL[DXR], 8-SL[DXR] and 14-SL
[DXR] vs SL[DXR] and SCR-SL[DXR]: p b 0.01; 1-SL[DXR] and 10-SL
[DXR], vs SL[DXR] and SCR-SL[DXR]: p b 0.05) (Fig. 4B). In contrast,
the effect of both targeted and untargeted formulations on HUVECs
was similar, although they were statistically signiﬁcant compared tountreated cells (p b 0.05). On the contrary, the evaluation of BrdU
uptake showed that all the NB-targeted formulations exerted an en-
hanced, statistically signiﬁcant anti-proliferative effect also on HUVECs
by decreasing the numbers of cells in S phase, compared to both
untargeted- and SCR-targeted liposomes (p b 0.001) (Fig. 4B).
3.4. Pharmacokinetic proﬁles and accelerated blood clearance
phenomenon of dual labeled peptide-targeted liposomes
As previously shown, long circulation times are required for small
liposomes to gain access to tumor sites [25]. In order to quantify the fate
of both the liposome and the drug, pharmacokinetic studies were
performed using dual labeled liposomes. Speciﬁcally, [3H]-CHOL-
labeled peptide-targeted liposomes, loaded with [14C]-labeled DXR
were evaluated [26] in nude mice without tumors. The results of the
pharmacokinetics are expressed as a percentage of the administered
dose of phospholipids (PL) and of the DXR remaining in the blood
(Fig. 5A). The results clearly indicate that each liposomal formulation
coupled to the ﬁve different peptides has good stability and long circu-
lation times,with about 15% of both the carriers and the drug remaining
in the blood 24 h after liposome inoculation.
Although other investigators reported that the ﬁrst injection of li-
posomal DXR fails to produce increased clearance of the second dose
[26], we also investigated the impact of the ﬁrst injection of our novel
peptide-targeted, DXR-loaded liposomes on inducing the accelerated
blood clearance (ABC) phenomenon. As expected, no enhanced clear-
ance of the second dose (pre-dosing) for both the carrier and the en-
capsulated drug was observed after the repeated injections of 5-SL
[DXR] (Fig. 5B) and of all the other peptide-targeted formulations
(not shown), conﬁrming that the ABC phenomenon does not occur
after repeated injections of our novel targeted liposomal DXR.
3.5. Peptide-targeted drug delivery nanocarriers have potentiated
therapeutic efﬁcacy
To evaluate the in vivo localization of liposomes-entrapped DXR,
we exploited its intrinsic ﬂuorescence as an indicator of the drug
amounts that reached the tumors. For these studies, mice bearing
orthotopic models of human NB were injected with a single bolus of
Fig. 6. Liposomes functionalized with selected peptides show potentiated therapeutic
efﬁcacy. A. Time-dependent anti-tumor effects of DXR-loaded, peptide-targeted
nanocarriers evaluated by the use of a luciferase-transfected human NB cell line
(GI-LI-N) orthotopically inoculated in animals. Treatment started twenty-one days
(T21) after tumor cell injection. Animals (5 animals/group) were treated i.v., once a
week for 3 weeks, with 5 mg/kg of DXR free, or encapsulated in either non-targeted
or peptide-targeted nanocarriers. SCR peptide-targeted nanocarriers were used as a
control. Control mice received HEPES-buffered saline. Tumor growth was monitored
by BLI at day 26, 33, and 40 after tumor challenge. Values are reported as fold increase
in tumor volume compared to pre-treatment (day 20). Exemplary pictures of X-ray ac-
quisitions one month after the end of treatment (day 65), corresponding to three mice
treated with SL[DXR], 5-SL[DXR] and 10-SL[DXR] are shown. B, C. The therapeutic ef-
fect of the targeted formulations was evaluated in terms of overall survival in two an-
imal models: HTLA-230 cells inoculated i.v. into the tail vein (pseudo-metastatic
model, 13 mice/group, B), GI-LI-N cells implanted into the adrenal gland (orthotopic
model, 8 mice/group, C). Statistical analysis: A), p versus SL[DXR]; B, C), p versus con-
trol, SL[DXR] and SCR-SL[DXR].
Fig. 5. Pharmacokinetic proﬁles and tumor accumulation of liposomes functionalized
with selected peptides in vivo. Mice were injected via the tail vein with either a single
dose (A; all peptide-targeted liposomes shown) or two doses (pre-dosing, B; 05-SL
[DXR] shown) of peptide-targeted, liposomes, dual labeled with the lipid tracer
[3H]-CHOL (PL) and the drug tracer [14C]-DXR. At selected time points (2, 12, 24, and
48 h) post-injection, blood was counted for 3H and 14C labels in a Packard
beta-counter. Points, average of three mice; bars, ±SD. PL: phospholipids. C. Mice bear-
ing orthotopic models of human NB were injected with a single bolus of doxorubicin
(DXR) (5 mg/kg/mouse), either free (Free DXR), or encapsulated in untargeted (SL
[DXR]) and peptide-targeted (1-SL[DXR], 5-SL[DXR], 8-SL[DXR], 10-SL[DXR], 14-SL
[DXR]) liposomes. Scrambled peptide-targeted formulation (SCR-SL[DXR]) was used
as a further control. Control mice received HEPES-buffered saline (3 animals/group).
Tumors were explanted 24 h after treatment, and the presence of DXR-associated ﬂuo-
rescence was evaluated by ﬂuorescence microscopy on 5-μm frozen tissue sections.
Speciﬁc ﬂuorescence is expressed by percent area of total area acquired. **, p b 0.01;
***, p b 0.001 versus control, SCR-SL[DXR] and SL[DXR].
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SL labeled with either scrambled peptide or NB peptide, and tumors
were explanted 24 h after treatment. Control mice received saline so-
lution. All the targeted formulations speciﬁcally accumulated into the
tumor masses (Fig. 5C). Signiﬁcantly increased amounts of DXR were
delivered by the liposomes functionalized with peptide #5 (5.1×
compared to the SCR-SL[DXR]), #8 (3.1×) and #10 (3.6×). The re-
sults of these tumor accumulation studies strongly support the use
of 5-SL[DXR], 8-SL[DXR], and 10-SL[DXR], either individually or in
combination, for targeted therapeutic approaches against NB.
In a ﬁrst set of therapeutic experiments we transduced GI-LI-N
cells with the reporter gene luciferase before inoculation into the
left adrenal glands of athymic mice. Injection of the various DXR for-
mulations started 21 days after cell implant, and tumor growth was
monitored by bioluminescence (BLI) once a week ﬁve days after
each treatment (days 26, 33 and 40). In this experimental setting
(Fig. 6A), free, as well as untargeted (SL) or scrambled peptide-
targeted (SCR-SL) DXR had very weak, if any, therapeutic readout.Conversely, treatment with almost all the targeted formulations
resulted in a delay of tumor progression; 5-SL[DXR] and 10-SL[DXR]
proved to be the most efﬁcient targeting systems, leading to a strong
and long-lasting, statistically signiﬁcant inhibition of primary tumor
growth (day 40, p b 0.001 vs SL[DXR]). Also 8-SL[DXR] and 14-SL
[DXR] showed a statistically signiﬁcant tumor growth arrest, but to
a lower extent, compared with untargeted liposomes (p b 0.05 vs SL
[DXR]). The long-lasting anti-tumor response caused by 5-SL[DXR]
and 10-SL[DXR] was conﬁrmed by X-ray analysis of NB-bearing
mice, performed one month after the end of the treatment (day 65).
Fig. 6A clearly shows abdominal tumor growth in mice injected
with SL[DXR], whereas tumors were barely detectable in both 5-SL
[DXR] and 10-SL[DXR] treated mice.
In a second set of experiments, the best candidates among the
novel peptide-targeted formulations were tested for their potential
to increase the life span of NB-bearing mice. Two aggressive animal
models of human NB were used, with cells inoculated either i.v. in
the tail vein (HTLA-230 cells, Fig. 6B), to mimic the spreading of
tumor cells and the minimal residual disease, or orthotopically in
the adrenal gland (GI-LI-N cells, Fig. 6C), to reﬂect the growth of ad-
vanced NB in children (large adrenal gland tumors and small metastatic
lesions). In bothmodels, 5-SL[DXR] and 10-SL[DXR] formulations led to
a signiﬁcant increase in the survival of NB-bearing mice, when com-
pared to control animals or to animals treated with DXR, either free
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targeted (SCR-SL[DXR]) formulations (Fig. 6B–C).
3.6. Biodistribution proﬁles of peptides 5 and 10-targeted liposomes
Biodistribution (BD) experiments of the most promising (in terms
of anti-tumor efﬁcacy) peptide 5- and 10-targeted DXR-loaded dual
labeled liposomes were performed in orthotopically injected
NB-bearing mice. BD proﬁles were evaluated in the tumor and in
the liver, spleen, kidney and heart, with the latter being an important
indicator of DXR-related cardiotoxicity (Richardson et al. Blood Rev
1997). Supplementary Fig. 1 shows a time-dependent tumor uptake
of each liposomal formulation, while negligible accumulation was re-
vealed in the heart at all time points, conﬁrming that both 5- and
10-SL[DXR] minimized nonspeciﬁc heart uptake. As expected, a
time-dependent liver and spleen accumulation of the injected 3H-la-
beled carrier was seen for each formulation tested. Accordingly with
the liposomal stability results showed in the pharmacokinetics pro-
ﬁles (Fig. 5A–B), also similar extent of the liposomal loaded-
14
C-DXR
(not shown) were found in each of the analyzed tissues.
4. Discussion
Herewe report the identiﬁcation ofﬁve novel peptide ligands selected
by combined in vitro/ex-vivo phage display screenings in preclinical
models of human neuroblastoma (NB). We show that corresponding
peptide-targeted drug delivery nanocarriers counteract NB progression
in biologically relevant animal models, with a substantial improvement
in their therapeutic efﬁcacy, compared to both free drug and untargeted
systems.
Chemotherapy remains the main treatment for most cancer types;
however, there is still no clinically available antineoplastic drug capable
of a highly selective action on the tumor mass. Despite some positive
hints of anti-cancer selectivity for targeted antibodies and small-
molecule inhibitors, the pitfalls of these approaches (low responsive-
ness, primary and secondary resistance, high costs) are much more
limiting than initially expected. Nanotechnology is providing powerful
tools for cancer treatment and prevention, but the successful achieve-
ment of a reduced toxicity in chemotherapy-driven side effects is not
yet satisfactorily correlated with a sustained increase in overall patient
survival [27]. For all these reasons, widespread efforts are presently
focused on the development of drug-targeting strategies that would
enhance the efﬁcacy of therapeutic agents (by increasing local concen-
tration) while reducing their toxic side effects (by decreasing systemic
exposure).
In tumors, both epithelial and stromal (e.g., endothelial) cells
express surface markers that are accessible from the circulation, but
are undetectable, inactive or inaccessible in normal tissues [28,29].
These markers can be exploited for a selective delivery of anticancer
agents to the tumor sites, therefore combining selectivity of the drug
nanocarriers with longevity in the bloodstream. Considering the variety
of cell types and of signaling pathways involved in the crosstalk be-
tween the tumor and its microenvironment, it is reasonable to expect
that a multi-target approach would lead to a substantially increased
therapeutic efﬁcacy. Screening phage-display peptide libraries on intact
cells or tissues allows the identiﬁcation of speciﬁc peptide ligands to be
exploited for systemic targeting throughout the circulation [30].
We have recently demonstrated that two phage display-derived
peptides, discovered previously in other tumor models, and recogniz-
ing separate epitopes of the tumor vasculature, increased the thera-
peutic effects of chemotherapy against preclinical models of human
NB when coupled at the external surface of liposomal formulations
[18]. We here report the identiﬁcation of new peptide sequences
obtained by direct screening of phage libraries on NB cells and fresh
tumors from NB-bearing mice. To our knowledge, such an approach,aimed at selecting speciﬁc NB-targeting moieties, has not been
applied before.
We validated 5 novel peptide sequences, namely #1-YEGLISR,
#5-HSYWLRS, #8-WSWPREL, #10-ALAAHKL (selected as ligands for
NB microenvironment) and #14-KSFFLSH (selected as a ligand for
the whole NB tumor mass) (Fig. 1), demonstrating their speciﬁc rec-
ognition of NB tumors in different preclinical settings. The overlay
binding assays performed on biopsies from NB patients (Fig. 2A)
showed that, although Phages #1, #5, #8, and #10 preferentially target
NB microenvironment, and while Phage #14 binds NB epithelium,
none of these phages univocally associates to speciﬁc tumor compo-
nents. In the case of overlay binding assays on mouse tissues (Fig. 2B),
the availability of a larger number of samples allowed a further charac-
terization of the NB masses by staining for Factor VIII (endothelial cells,
stroma), CD31 (endothelial/hematopoietic cells), SMA (perivascular
cells, cancer-associated ﬁbroblasts), and collagen I (stroma, cancer-
associated ﬁbroblasts), for comparisonwith the tissue binding of select-
ed phage. The results of this second panel of overlay assays substantially
conﬁrmed the staining patterns observed on human tissues, suggesting
that the molecular target(s) of the selected NB-binding peptides
might be expressed, although in different amounts, by different cell
types. These results are consistent with the fact that relatively low-
stringency phage display outputs reﬂect the non-discrete nature of
biomarker distribution in normal/tumor tissues. In other words, with
the screening approach described here it is possible to identify ligands
not only for receptors that are absent in control and present in target
tissues, but also (and more generally) that are just enriched in target
tissues.
Globally, our results show that #5-HSYWLRS is the most promising
ligand for future developments, in terms of both in vitro binding and
in vivo targeting of different models of human NB. Interestingly,
this peptide shares similarity with the FF/YXLRS motif, isolated by
Karjalainen K. et al. [31], and characterized as a speciﬁc ligand of
neuropilin-1 (NRP-1), despite the lack of the canonical NRP-1-
recognition sequences R/KXXR/K and RRXR also identiﬁed by phage dis-
play [32,33]. Karjalainen K. and colleagues showed that this sequence is
responsible for the enhanced internalization of an apoptosis-inducing
moiety into leukemia and lymphoma cells, leading to increased tumor
cell killing. Although a deeper investigation is needed to understand
whether the ﬂanking regions in #5-HSYWLRS inﬂuence its binding
capability, we may speculate that this peptide might recognize the
NRP-1 receptor expressed in NB tumors [34], thus mediating a speciﬁc
targeting drug delivery, when coupled at the external surface of doxo-
rubicin (DXR)-loaded liposomes.
We used two aggressive models of human NB to investigate the ef-
ﬁcacy of our targeted formulation, mimicking either the spreading of
tumor cells and minimal residual disease (i.v. cell inoculation), or the
growth of advanced NB in children that appear as large adrenal gland
tumors and small metastatic lesions (orthotopic implant into the adre-
nal gland) [16,19]. Remarkably, #5-HSYWLRS and#10-ALAAHKL confer
to the cognate-targeted formulations a signiﬁcant therapeutic efﬁcacy
in the two preclinical NB models that were tested (Fig. 6A–C). This
result indicates that either peptide is a valuable targeting moiety for
the delivery of encapsulated DXR to circulating tumor cells and
established tumor masses. #14-KSFFLSH- and, accordingly with its
tumor accumulation ability (Fig. 5C), #8-WSWPREL-targeted liposomes
were capable of partially arresting orthotopically implanted NB tumors
(Fig. 6A), without, however, any prolonged survival time showed. These
data support the assumption that, although all the selected phage-
displayed peptides recognize NB-speciﬁc markers, they might have dif-
ferent targeting properties, e.g. target availability or afﬁnity. Conversely,
#1-YEGLISR peptide sequence, did not confer to cognate targeted
nanocarriers a statistically signiﬁcant and long lasting therapeutic efﬁ-
cacy, at least at the doses and schedule treatment used. However,
considering the overall capability of homing to tumors in our NBmurine
model all these peptides, alone or in combination, might be exploited
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systems of NB or used in combined therapeutic setting. Indeed, the
multi-targeting approach (theragnostics) to improve, for instance,mag-
netic resonance imaging of angiogenesis with a liposomal contrast
agent, is a promising clinical strategy [35].
In this paper we demonstrated that the enhanced permeability and
retention (EPR) effect was very weak on each neuroblastoma animal
model used. Our results seem to be in accordance with the recent
concept on EPR [36]. EPR heterogeneity effect in different tumors as
well as limited experimental data from patients on the effectiveness
of this mechanism, seems to hamper the progress in developing drugs
using this approach. Our data are also in agreement with our past and
recent published ﬁndings, in which we showed that nanocarriers
were always able to yield increased anti-neuroblastoma effects via an
active targeting, when compared to the passive, EPR-driven, anti-
tumor efﬁcacy [16,37].
Despite the absence of long-term survivors in NB-bearing mice
treated with single formulations, the identiﬁcation of various NB pep-
tide ligands opens the way for developing, in the next future, simulta-
neous or sequential multi-targeting systems for the treatment of NB,
as proposed by Ferrari's team for other cancers [38–40]. The use of
peptides against different receptors may promote, in principle, syner-
gistic targeting effects, and therefore, might improve the therapeutic
response to anticancer nanodrugs. This view is supported by recent
ﬁndings showing that hitting tumor endothelial and perivascular
cells with separate peptide-targeted nanoparticles [18], or tumor
cells and tumor microenvironment with the same nanoparticles
[41], results in an improvement in the therapeutic activity of antican-
cer drug-loaded liposomes. Further investigation is necessary to iden-
tify the receptors recognized by the peptides discovered in the
present work. Undoubtedly, these notions would be of extreme im-
portance, particularly by informing the choice of the optimal treat-
ment schedule in a multi-target therapy setting, thereby avoiding
redundancy of targets and increasing the anti-tumor effects.
Finally, the most promising, in terms of anti-tumor efﬁcacy, pep-
tide 5- and 10-targeted DXR-loaded liposomes showed good stability
and long circulation times, and showed time-dependent tumor accu-
mulation, while sparing heart uptake. These data conﬁrm the impor-
tance of performing phage display screening on preclinical models of
human NB, an approach that enabled the ﬁnding of more selective
tumor-targeting moieties that can be expected to substantially im-
prove current therapeutic regimens, and have the potential of being
translated into the clinical practice.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.jconrel.2013.04.029.
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